Tango Therapeutics Approves Key Proposals at Annual Meeting

Tango Therapeutics ( (TNGX) ) just unveiled an announcement.

On June 5, 2025, Tango Therapeutics held its annual stockholders meeting where several key proposals were approved. Notably, the amendment to increase authorized common stock shares from 200 million to 400 million was passed, potentially enhancing the company’s capital structure and flexibility. Additionally, Lesley Ann Calhoun was elected as a Class I director, and PricewaterhouseCoopers, LLP was ratified as the independent accounting firm for the fiscal year ending December 31, 2025. The stockholders also approved executive compensation policies and decided on an annual frequency for future advisory votes on executive compensation.

The most recent analyst rating on (TNGX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.

Spark’s Take on TNGX Stock

According to Spark, TipRanks’ AI Analyst, TNGX is a Neutral.

The overall score for Tango Therapeutics reflects significant financial challenges and an unattractive valuation due to negative earnings. While technical indicators show current positive momentum, the overbought condition poses a risk. The company’s cautious leverage is a positive aspect but not sufficient to overcome the financial hurdles.

To see Spark’s full report on TNGX stock, click here.

More about Tango Therapeutics

Tango Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of targeted cancer therapies. The company aims to leverage genetic vulnerabilities in cancer cells to create effective treatments.

Average Trading Volume: 1,909,948

Technical Sentiment Signal: Hold

Current Market Cap: $354.4M

Learn more about TNGX stock on TipRanks’ Stock Analysis page.